期刊文献+

外周T细胞淋巴瘤的诊断和治疗进展 被引量:12

Progress of diagnosis and treatment in peripheral T celllymphoma
原文传递
导出
摘要 外周T细胞淋巴瘤(PTCL)是一组分子生物学上异质性很大,并且尚未完全认识清楚的T细胞肿瘤,根据WHO2008淋巴造血组织疾病分类,PTCL约占非霍奇金淋巴瘤(NHL)的10%[1],最常见的亚型包括非特指型PTCL(PTCL—NOS,26%)、血管免疫母细胞T细胞淋巴瘤(AITL,18.5%)、NK/T细胞淋巴瘤(10%)、成人T细胞白血病/淋巴瘤(ATLL,10%)、ALK阳性间变性大细胞淋巴瘤(ALK’ALCL,7%)和ALK阴性的ALCL(ALkALCL,6%)。
作者 刘霆
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第4期361-366,共6页 Chinese Journal of Hematology
  • 相关文献

参考文献44

  • 1Savage KJ. Peripheral T-cell lymphomas [J]. Blood Rev, 2007, 21(4):201-216.
  • 2Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes [J]. J Clin Oncol, 2008, 26(25): 4124-4130.
  • 3Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American insti- tution by the WHO classification [ J ]. Ann Oncol, 2004, 15 (10): 1467-1475.
  • 4Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group [ J ]. Blood, 2010, 116( 18):3418-3425.
  • 5Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treat- ment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience[J]. Cancer, 2005, 103( 10): 2091-2098.
  • 6Dunleavy K, Shovlin M, Pittaluga S, et al. DA-EPOCH chemo- therapy is highly effective in ALK-positive and ALK-negative ALCL: results of a prospective study of PTCL subtypes in adults [J]. Blood, 2011, liB:Abstract 1618.
  • 7Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase Ⅱ study [J]. Cancer Chemother Pharmacol, 2007, 60( 1 ):129-134.
  • 8Gallamini A, Zaja F, Patti C, et al. Alemtuzumah (Campath-Ⅲ) and CHOP chemotherapy as first- line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multieenter trial[J]. Blood, 2007, 110(7):2316-2323.
  • 9Janik J, Dunleauy K, Pittaluga S, et al. A pilot study of Campath- 1 with dose-adjusted EPOCH in CD52 expressing aggressive T- cell malignancies[J]. Blood, 2005, 106: Abstract 33348.
  • 10Foss FM, Sjak-Shie N, Goy A, et al. A multicenter phase Ⅱ trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study [J] . Leuk Lymphoma, 2013, 54(7):1373-1379.

同被引文献175

  • 1王广梅.中西医结合治疗组织细胞坏死性淋巴结炎效果观察[J].医学信息(医学与计算机应用),2014,0(29):194-194. 被引量:1
  • 2马小军,王爱霞,邓国华,盛瑞媛.不明原因发热449例临床分析[J].中华内科杂志,2004,43(9):682-685. 被引量:116
  • 3纪小龙,徐长江,刘雨清.我国淋巴瘤的临床病理特点──附1289例分析[J].肿瘤防治研究,1996,23(5):268-269. 被引量:25
  • 4陈定宝,沈丹华.复合性淋巴瘤的病理学特点[J].诊断病理学杂志,2007,14(2):141-144. 被引量:10
  • 5Savage KJ. Aggressive peripheral T-cell lymphomas ( specified and unspecified types ) [ J ]. Hematology Am Soc Hematol Educ Program, 2005: 267-277.
  • 6Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project [ J ]. Blood, 2011,117(12) :3402-3408.
  • 7Escalen MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience [ J ]. Cancer, 2005, 103 (10) : 2091-2098.
  • 8Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues [ M ] . 4th ed. Lyon : IARC ,2008.
  • 9Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin' s Disease Staging Classification [J]. Cancer Res, 1971, 31 ( 11 ) : 1860-1861.
  • 10Savage KJ. Peripheral T-cell lymphomas [ J ]. Blood Rev, 2007, 21(4) : 201-216.

引证文献12

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部